Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tranexamic acid + misoprostol
- Development stage
- Phase 4
- Lead developer
- PATH
- Modality
- Small Molecules
- Administration
- Intravenous, Sublingual
01
Overview
A combination of tranexamic acid, an antifibrinolytic agent that inhibits plasminogen activation, and misoprostol, a prostaglandin E1 analog that stimulates uterine contractions. This combination is primarily used to prevent and treat postpartum hemorrhage, particularly in high-risk patients undergoing cesarean delivery or other obstetric procedures. Clinical studies show it significantly reduces blood loss compared to oxytocin alone or carbetocin.
- Other names
- misoprostol and tranexamic acidtranexamic acid + misoprostol
02
Targets
PLG (Plasminogen)
Beyond the preview
Go deeper on tranexamic acid + misoprostol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tranexamic acid + misoprostol.